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A report on the RNAi symposium at the Cambridge
Healthtech Institute ‘Beyond Genome’ Conference, San
Francisco, USA, 21-24 June 2004. 
We have come so far so fast in understanding RNA interference
(RNAi) and its central role in biology. Rarely has a novel
mechanism in molecular genetics had such broad implications,
ranging from gene therapy and drug discovery to our very
understanding of what the word ‘gene’ means. Every major
pharmaceutical company has a substantial effort now in
RNAi technology, and among the smaller biotechnology
companies RNAi is the mainstay of several, with catchy
names like Sirna Therapeutics. RNAi is the current buzzword
in academic and corporate circles, and it certainly captured
the imagination at the RNAi symposium of Cambridge
Healthtech Institute’s ‘Beyond Genome’ conference. This
report focuses on work presented at the meeting that aims to
elucidate the natural cellular role of small interfering RNA
(siRNA) molecules and microRNAs (miRNAs), and some of
the very exciting advances in the use of RNAi technology in
drug discovery and therapeutics.
It is becoming ever clearer that siRNA molecules of various
sorts play roles in normal development in a wide variety of
organisms. The first of this class of molecules to be discovered,
lin-4 in  Caenorhabditis elegans, is transcribed as a 61
nucleotide precursor to a 22 nucleotide miRNA that has a
role in the regulation of developmental timing. Pre-miRNAs
are processed by two different members of the RNase III
family, Drosha and Dicer, explained John Rossi (City of
Hope National Medical Center, Duarte, USA). An miRNA
achieves its functional state as part of a nucleoprotein
complex called RISC (RNA-induced silencing complex).
Although miRNA molecules are thought to interfere with
mRNAs, there is evidence that some of them, and other non-
coding RNA molecules, are involved in transcriptional
silencing and heterochromatin formation as well.
The concept of RNAi has revised our thinking in many
arenas. First, post-transcriptional regulation has always
played second fiddle to transcriptional regulation for stu-
dents of metazoan gene expression. Now we know that inter-
fering RNAs are not just the sledge-hammers we can use to
inhibit expression in an experimental system, but are in fact
an integral part of the fine-tuning of gene expression in
normal cells. The class of miRNA genes, which produce
short-hairpin RNA (shRNA) precursors of interfering RNA
molecules, probably numbers in the thousands, representing
a category of trans-acting regulatory genes never before
imagined. RNAi has become the tool of choice in many
knock-out or knock-down gene-expression experiments, now
nearly as ubiquitous in laboratories as PCR. Using RNAi as a
tool shows great promise in the discovery of new drug targets,
and interfering RNAs or vectors producing precursor RNA
molecules are already in testing as therapeutic agents.
Several presentations at the meeting help reinforce the idea
that miRNAs may have a prominent role in development.
Kenneth Kosik (Harvard Medical School, Boston, USA) has
identified many miRNAs in neural tissue. A subset of these
was predominantly expressed in or confined to neural cells
in mammals, and some of these miRNAs were developmental-
stage-specific. Evidence that key developmental gene clusters
contain and are regulated by miRNAs was presented by
I-Hung Shih (Massachusetts Institute of Technology (MIT)
and Whitehead Institute, Cambridge, USA), who described
the occurrence of miRNA genes (including miR-196 and
miR-10) within insect and mammalian homeobox (HOX)
gene clusters. Several of the HOX genes are down regulated
in response to expression of miR-196 in cell culture. In what
is apparently the first direct validation of miRNA-mediated
repression in vivo in mammalian systems, Shih and colleagues
subsequently showed that miR-196 mediates cleavage of its
target, HOXB, in mouse embryos. Shih believes that miRNA-
regulated targets in mammals are involved in a broad range
of functions, including signaling and cell growth, with about
20% of the targets being transcription factors; Shih thereforecontends that miRNAs will become increasingly important
in our understanding of developmental events.
According to Markus Stoffel (Rockefeller University, New
York, USA), pancreatic beta cells use RNAi in the production
of insulin. This finding is especially relevant today, when the
incidence of type II diabetes and of obesity is nearing epidemic
proportions in industrialized nations, with type II diabetes
affecting nearly 12 million people in the USA. Stoffel found
novel miRNAs whose expression is confined to pancreatic
beta cells, and showed that one of them (mi208) inhibits
glucose-stimulated insulin secretion. This is not only a
fascinating example of the role of endogenous interfering
RNA molecules in development and physiology, but it also
suggests novel means of therapeutic intervention.
Complex diseases like cancer and diabetes may be difficult to
study in traditional experimental systems. Luk Van Parijs
(MIT, Cambridge, USA) thinks RNAi is the solution to these
problems. NOD mice are commonly used to study type I
diabetes; in these animals, an autoimmune response rapidly
destroys pancreatic beta cells. Van Parijs used RNAi to
knock down expression of the immune cell receptor CD8 and
observed a marked reduction in the occurrence of diabetes in
NOD mice. This finding suggests that inhibition of the
expression of candidate disease-susceptibility genes using
RNAi can provide useful data. Van Parijs has extended his
approach to the study of cancer-susceptibility genes. The
typical output from a microarray experiment is a list of genes
whose expression levels differ significantly between normal
and cancer tissue, but this cannot give any indication of a
causal relationship. In order to separate cause from effect,
Van Parijs has used RNAi sequentially on a set of genes
whose expression is altered with the aim of determining
whether or not the disease state is abrogated by repression
of these genes. For instance, if expression of a gene is
increased in non-Hodgkin’s lymphoma, and if that increase
is of a causal rather than a correlative nature, then a knock-
down in expression with RNAi should result in an abrogation
of the phenotype. The rapidity of RNAi experiments allows
the study of single-gene and multi-gene expression changes.
To facilitate this work, Van Parijs has developed a bifunctional
lentiviral vector which expresses both Myc and a particular
shRNA. The shRNAs were obtained from an RNAi library
focusing on known or putative cytokine-regulated genes,
with four shRNAs tested for each gene. The results begin to
delineate a network of genes that regulate c-Myc-induced
transformation and might provide novel therapeutic targets.
William Pardridge (University of California, Los Angeles,
USA) used intravenous injection of RNAi as an astoundingly
successful therapy for brain cancer in mice. The epidermal
growth factor receptor (EGFR) plays an oncogenic role in
90% of primary brain cancers and in a substantial fraction of
metastases. Pardridge’s group introduced an RNA to interfere
with EGFR via a nonviral vector in immunoliposomes with
cell-surface receptors that target them to brain. Thus over-
coming the blood-brain barrier, the group achieved an 88%
increase in survival time in mice, and a 95% knockdown in
EGFR expression in cell culture. Recently published work
has drawn attention to Iressa, a drug targeting EGFR, as an
example in which pharamacogenomic analysis is useful, as
the drug is efficacious in patients with certain EGFR muta-
tions but not others. Pardridge contends that, unlike Iressa,
RNAi-based gene therapies can be designed for both normal
EGFR and the mutant forms of EGFR found in many tumors. 
Continuing the theme of RNAi-based therapies, Beverly
Davidson (University of Iowa, Iowa City, USA) presented a
novel and exciting approach to therapy for neurodegenerative
disease. Spinocerebellar ataxia type 1 (SCA1) results from
the expansion of a trinucleotide repeat (CAG) in the coding
region of the ataxin-1 gene, resulting in a lengthened
polyglutamine (polyQ) tract in the protein itself. Over time,
this leads to the accumulation of intranuclear protein aggre-
gates and progressive neural degeneration. Davidson worked
with a transgenic mouse model of SCA1 in which expression
of the mutant human ataxin-1 gene is confined to Purkinje
cells of the cerebellum. The mice demonstrate both typical
brain pathology and ataxia in a ‘rotarod’ test that requires
them to cling on to a rod while it rotates. Davidson and her
colleagues prepared an adeno-associated virus (AAV) vector
containing an shRNA recognizing the mutant ataxin-1
transgene. This was then delivered by intracerebellar
injection directly to the brain region affected. Treated
animals showed a significant improvement in performance
on the rotarod test, and brain sections revealed improved
histology.  Ataxin-1 inclusions in the Purkinje cell nuclei
were also completely resolved. The findings are especially
promising because several additional ataxias, including
Huntington disease, are also caused by polyQ tracts, and
RNAi may prove an effective means to treat them. Davidson
cautioned, however, that some interfering RNAs were not
successful at inhibiting ataxin-1, and considerable trial-and-
error may be required en route to a successful therapy.
The key message from the conference is that we have by no
means seen the last of RNAi as an intriguing biological
phenomenon, a tool in basic research, and a new molecular
approach for the pharmaceutical industry. Its rapid rise
from startling new phenomenon to canon leaves little room
for caution. But Aimee Jackson (Rosetta Inpharmatics,
Seattle, USA) and Kevin Fitzgerald (Bristol-Myers-Squibb,
Princeton, USA) noted that RNAi is not the magic bullet it
once seemed; off-target effects are common and considerable
optimization is necessary. Fitzgerald further emphasized
that while typical small molecular drugs inhibit a particular
function of a protein, leaving the rest of the protein and all of
its interactions intact, RNAi can completely eliminate the
target protein, abolishing all of its complex interactions at
the same time. While RNAi plays a key role in basic
research in genome biology and in drug-target validation and
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Genome Biology 2004, 5:342therapeutics, the other symposia at the conference dealt
with the fields of bioinformatics, proteomics and systems
biology. These latter areas, taken together, are becoming
increasingly important as the drivers of new information,
and of new ways of looking at the vast data available to us
now. Despite the rapid advances in RNAi and in the ability to
characterize cellular proteins on a large scale (proteomics),
informatics approaches are needed to speed up an otherwise
excruciatingly slow and costly process of drug development.
Systems approaches promise to model cellular processes in
much the same way that aeronautical engineers model planes
before building and flying them. In silico testing prior to
animal and human studies, advocated by the Institute for
Systems Biology (Seattle, USA) and companies like Entelos
(Foster City, USA), is part of the US Food and Drug Adminis-
tration’s new ‘critical path’ initiative to move more novel drugs
to market more efficiently and less expensively.
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
http://genomebiology.com/2004/5/9/342                                                          Genome Biology 2004, Volume 5, Issue 9, Article 342 Goldman  342.3
Genome Biology 2004, 5:342